Effect of the oral iron chelator deferiprone in diabetic nephropathy rats Highlights • Deferiprone treatment alleviated inflammation infiltrates, and collagenous fibrosis in DN rats, and inhibited the expression of NF-κB, MCP-1, COX-2, and nitrotyrosine, which were overexpressed in DN rats.
Introduction
Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes and is a leading cause of end-stage renal disease (ESRD) worldwide. 1 The manifestation of DN is typically microalbuminuria; 2 other characteristic features include thickening of glomerular basement membranes and glomerular hyperfiltration, 3 as well as tubulointerstitial fibrosis. 4 Diabetic nephropathy is a consequence of the actions of certain cytokines and growth factors, such as transforming growth factor (TGF)-β. 5 Inflammation plays a central role in the development and progression of DN. 6 However, the specifics of the pathogenesis and progression of DN remain to be fully elucidated.
Monocyte chemotactic protein (MCP)-1 is upregulated in tubulointerstitial lesions of human DN. 7 Podocyte cyclo-oxygenase (COX)-2 exacerbates DN by increasing podocyte (pro)renin receptor expression. 8 Streptozocin (STZ)-induced DN rats exhibit significant changes in renal function, increased oxidativenitrosative stress, increased tumor necrosis factor (TNF)-α, TGF-β1, and caspase-3 activity in cytoplasmic lysates, and increased active p65 of nuclear factor (NF)-κB in the kidney. 9 Iron, an essential trace metal for organisms, catalyses highly toxic hydroxyl radicals via the Fenton/Haber-Weiss reaction, inducing oxidative stress. 10 It has been reported that iron restriction prevents the development of DN by suppressing oxidative stress. 11 In addition, iron chelators have been proposed to play an important role in chronic inflammatory disease. 12 Thus, we assumed that iron chelation may also have a renoprotective effect in DN. In a previous study, we found that an iron chelator alleviated tubulointerstitial fibrosis in DN rats by inhibiting the expressions of tenascin C, TGF-β1, fibronectin 1 (Fn1), and collagen IV. 13 In the present study, we further investigated the effects of oral administration of deferiprone, an iron chelator, on the development of DN and the mechanisms involved by focusing on the expression of inflammatory factors and other cytokines.
Methods

Animals
Thirty-two male Wistar rats (180-220 g, 6 weeks old) were purchased from the Laboratory Animal Center of First Clinical College of Harbin Medical University (Harbin, China). Rats were housed in an animal facility under a 12-h light-dark cycle with ad libitum access to water and diet. All animal protocols for this study were in compliance with the guidelines for the animal care of the First Affiliated Hospital of Harbin Medical University and the study was approved by the Ethics Committee of The First Affiliated Hospital of Harbin Medical University.
Diabetic nephropathy model and treatment
Eight rats were randomly allocated into the control group, with the remaining 24 rats used to establish a DN model. To create the DN rat model, rats were fed of 6 weeks with a high-carbohydrate, high-fat diet (5% protein, 60% carbohydrate, 32 % fat) and then injected with 35 mg/kg streptozotocin (STZ; dissolved in 10 mM citrate buffer, pH 4.5; Sigma-Aldrich, St Louis, MO, USA) into the vena caudalis. Rats in the control group were injected with an equivalent volume of sodium citrate buffer after 6 weeks feeding of standard rat chow. Five days after STZ or sodium citrate buffer injection, blood glucose levels in tail blood samples from all rats were measured using a glucometer (Bayer Diagnostics, Elkhart, IN, USA). In addition, 24-h urine samples were collected and urinary protein content was determined by immunoassay (DCA 2000 System; Bayer Diagnostics). Non-fasting blood glucose >300 mg/dL (16.7 mmol/L), insulin resistance, and urine protein >30 mg/24 h indicated successful creation of a DN model. The DN model rats were further subdivided three groups: an untreated groups and two groups treated with either 50 or 100 mg/kg per day deferiprone (Apopharma, Toronto, Canada). Deferiprone was administered orally starting 72 h after STZ injection for a total of 20 weeks. Physiological and pathological indices of DN rats (e.g. serum iron, ferritin, total iron binding capacity [TIBC] , transferrin saturation, serum creatinine, triglyceride, cholesterol, superoxide dismutase [SOD] , and methane dicarboxylic aldehyde [MDA], were determined.
After 20 weeks treatment with deferiprone, rats were anesthetized with pentobarbital sodium (35 mg/kg, i. p.) and the kidneys were perfused with ice-cold physiological saline through the renal artery. Kidney tissues were removed for experiments.
Histopathological changes to renal tissues
Renal tissues (3-μm sections) were stained with hematoxylin-eosin (HE) and Masson trichrome stain as described previously. 14, 15 Interstitial fibrosis was defined by the presence of interstitial collagen in sections stained with Masson's trichrome. 16 Tissue structures were visualized using transmission electron microscopy (TEM; JEM 1230; JEOL, Tokyo, Japan) at 80.0 kV, as described previously. 17, 18 Reverse transcription-polymerase chain reaction Total RNA from renal tissues was isolated using TRIzol reagent (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. Purified total RNA was reverse transcribed to cDNA. The cDNA was then subjected to polymerase chain reaction (PCR) using a commercially available kit (Takara, Dalian, China). The primer sequences and the length of the NF-κB, MCP-1, matrix metalloproteinase (MMP)-9, tissue-specific inhibitor of metalloproteinase (TIMP)-1, COX-2, and nitrotyrosine products are listed in Table 1 . The following conditions were used for amplification: 95°C for 5 min, followed by 35 cycles of 94°C for 45 s, 58°C for 30 s, and 72°C for 1 min. β-Actin was used as an internal control. The PCR products were separated by 20 % agarose gel electrophoresis and visualized by ethidium bromide staining. The mRNA levels of these factors were quantified using the Quantity One Analysis System (Bio-Rad, Hercules, CA, USA).
Western blotting analysis
Renal cortical tissues were lysed with RIPA buffer and total proteins were extracted and quantified using a bovine serum albumin (BSA) kit (Sigma). A total of 100 μg protein was loaded onto sodium dodecyl sulfate (SDS)-polyacrylamide gels and blotted onto nitrocellulose membranes. The membranes were blocked in 5% skim milk and then incubated with primary antibodies against NF-κB, MMP-9, TIMP-1, MCP-1, COX-2, and β-actin (all 1 : 1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. Blots were then treated with a secondary antibody (1 : 2000 dilution; Zhongshan Goldenbridge Biotechnology, Beijing, China) for 30 min at 37°C, and bands were developed using enhanced chemiluminescence (ECL) reagent (Amersham Biosciences, Pittsburgh, PA, USA) and quantified using a luminescent image analyzer (LAS-1000 plus; Fujifilm, Tokyo, Japan).
Immunohistochemistry
Paraffin sections (3 μm) were deparaffinized with three changes of 100% Histo-Clear (National Diagnostics, Atlanta, GA, USA), rehydrated with graded ethanol baths, and blocked with 0.3% H 2 O 2 . Sections were then incubated overnight with antibodies against NF-κB, MMP-9, TIMP-1, MCP-1 and nitrotyrosine (all 1 : 100; Santa Cruz Biotechnology). Sections without primary antibodies were used as negative controls. Ten random tubulointerstitial fields were selected to evaluate the degree of positive immunostaining in each rat by scoring as follows: negative (-) sections were scored 0; weakly positive staining (+) was scored 1; positive staining (++) was scored 2; and strong positive staining (+++) was scored 3. The total score for each group was calculated by multiplying the positive scores by the numbers of sections evaluated.
Statistical analysis
Statistical analyses were performed using SAS version 9.1.3 (SAS Institute, Cary, NC, USA). Data are presented as the mean ± SD. Comparisons among four groups were made by analysis of variance (ANOVA) followed by a post hoc least squares method (LSM) test. Two-sided P < 0.05 was considered to be significant. Table 2 summarizes the physiological and pathological data of rats in each group. A successful DN rat model was established (non-fasting blood glucose 20.09 ± 4.76 mmol/L, insulin resistance index 5.63 ± 0.5, and urine protein 35.26 ± 9.46 mg/24 h). There were significant increases in transferrin saturation, triglyceride, cholesterol, and MDA, and significant decreases in TIBC and SOD in the DN compared with the control group. These increases in transferrin saturation, triglyceride, cholesterol, and MDA were inhibited by administration of deferiprone. Furthermore, HE staining revealed glomerular capillary basement membrane thickening and mesangial area broadening in DN rats, with these pathological changes ameliorated by deferiprone (Fig. 1) . Masson staining revealed a significant increase in inflammatory cell infiltrates in the interstitium and collagenous fibers in DN compared with control rats, and these NF-κB, nuclear factor kappa B; MCP-1, monocyte chemotactic protein-1; MMP-9, matrix metalloproteinase 9; TIMP-1, tissue-specific inhibitor of metalloproteinase 1; COX-2, cyclo-oxygenase-2.
Results
Histopathological changes to renal tissues
changes were obviously ameliorated by deferiprone (Fig. 2) .
As shown in Fig. 3 , TEM imaging revealed significant renal tubular epithelial cell injury in the DN group. Degenerated mitochondrial vacuoles, abundant lysosome in the renal tubular epithelial cell cytoplasm, a broadened perinuclear space, loosened and vague mitochondrial ridge structures and disordered arrangement, and mild microvilli fusion were observed in tissues from DN rats. These features were significantly improved by deferiprone treatment. Data are the mean ± SD (n = 8 rats in each group). *P < 0.05**P < 0.01 compared with the control group; † P<0.05 ‡ P < 0.01 compared with the DN group; § P < 0.05**P < 0.01 compared with the DN + 50 mg/kg per day deferiprone group. 1 Insulin resistance was measured by hyperinsulinaemic-euglycaemic clamp.
TIBC, total iron binding capacity; SOD, superoxide dismutase; MDA, methane dicarboxylic aldehyde. Oral deferiprone for DN rats C. ZOU et al.
NF-κB, TIMP-1, MCP-1, and COX-2 mRNA and protein was observed in kidneys of DN rats, but this was downregulated by oral administration of deferiprone. However, MMP9 mRNA expression decreased in DN rats, and was increased by deferiprone. There was no significant difference between the two doses of deferiprone.
Immunohistochemistry for NF-κB, MMP-9, TIMP-1, MCP-1, and nitrotyrosine
Immunohistochemistry revealed that NF-κB, TIMP-1, MCP-1, and nitrotyrosine expression was significantly higher in DN than control rats, and that the increased expression in DN rats was effectively inhibited by oral Oral deferiprone for DN rats C. ZOU et al.
deferiprone. However, MMP-9 expression decreased in DN rats, and was increased by deferiprone (Fig. 5) . There was no significant difference between the two doses of deferiprone.
Discussion
Iron catalyses glycosylation and oxidation of proteins, 19, 20 which contributes to various complications of diabetes, 21 including DN. 22 Increased iron concentrations have been found in kidneys of human DN, 23, 24 and iron is involved in the accelerated course of DN due to oxidative stress and inflammation. [25] [26] [27] A previous study reported the anti-inflammatory effects of deferiprone in wound healing in rats. 28 The iron chelator deferiprone is primarily used in the treatment of thalassemia, and its long-term use has now been proved not to induce hepatic fibrosis. 29, 30 In the present study, we investigated the effects deferiprone in DN rats. Pathogenetic mechanisms involving oxidative stress, inflammation and fibrosis for DN 31 were considered. Histopathological observations confirmed the repair function and anti-fibrotic effects of deferiprone. The results of PCR, western blot and immunohistochemistry analyses suggested deferiprone probably exerts its function by inhibiting some oxidative, proinflammatory, and profibrotic factors, such as NF-κB, MCP-1, MMP-9, TIMP-1, COX-2, and nitrotyrosine.
Nuclear factor-κB is one of the key regulatory molecules in oxidative stress-induced cell activation. 32 Nuclear factor-κB regulates genes like those encoding the chemokines MCP-1 and regulated upon activation, normal T expressed and secreted (RANTES), which are involved in the progression of renal disease. 16 
Figure 4
Expression of nuclear factor (NF)-κB, monocyte chemotactic protein (MCP)-1, matrix metalloproteinase (MMP)-9, tissue-specific inhibitor of metalloproteinase (TIMP)-1, and cyclo-oxygenase (COX)-2 mRNA (a) and protein (b) in the control group, diabetic nephropathy (DN) rats and DN rats treated with 50 or 100 mg/kg per day deferiprone. Graphs show mean ± SD relative expression, normalized against β-actin, with representative blots shown on the right. *P < 0.05 compared with the control group; † P < 0.05 compared with DN.
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Upregulation of MCP-1 is involved in the progressive tubulointerstitial damage in DN 7, 33 and it has been proposed as a new diagnostic marker and therapeutic target for progressive renal injury in DN. 34 In the present study, the expression of MCP-1 and NF-κB was elevated in DN rats, and both were downregulated following deferiprone treatment. This suggests that deferiprone may have an effect on oxidative stress-induced renal injury.
Nitrotyrosine has been identified as an indicator of cell damage, inflammation, and nitric oxide (NO)-induced oxidative stress. 35 It is involved in the development of diabetic complications. 36 In the present study, nitrotyrosine expression was increased in DN rats, which is consistent with previous findings 37 and is indicative of tissue damage originating from oxidative stress. Deferiprone potently inhibits hydroxyl radical production in oxidative damage-related disease. 38 In the present study, the overexpression of nitrotyrosine in DN rats was significantly inhibited by oral administration of deferiprone. These results indicate that deferiprone improves the symptoms of DN in part by inhibiting oxidative stress.
Both NO and oxidative stress contribute to proinflammatory cytokine toxicity, which plays a critical role in Figure 5 Immunohistochemistry (IHC) for monocyte chemotactic protein (MCP)-1 (original magnification ×400), nuclear factor (NF)-κB (original magnification ×400), matrix metalloproteinase (MMP)-9 (original magnification ×200), tissue-specific inhibitor of metalloproteinase (TIMP)-1 (original magnification ×200), and nitrotyrosine (original magnification ×200) in the control group, diabetic nephropathy (DN) rats and DN rats treated with 50 or 100 mg/kg per day deferiprone. Representative images are shown for IHC for NF-κB, MMP-9, TIMP-1, MCP-1, and nitrotyrosine, whereas graphs show total scores of IHC in the control group, DN rats and DN rats treated with 50 or 100 mg/kg per day deferiprone. the development of DN. 6 Thus, we also evaluated the expression of the inflammatory factor COX-2 in the present study. Under normal conditions, COX-2 is not expressed in most cells, but expression is elevated during inflammation. Diabetic nephropathy increases podocyte COX-2 expression, and inhibition of COX-2 reduces proteinuria and glomerular injury in a diabetes model. 8 The results of the present study indicate that deferiprone can inhibit the expression of COX-2 in a rat model of DN.
Expression of MMP-9 was significantly lower in DN than control rats. Matrix metalloproteinase-9 (92 kDa) is also known as Type IV collagenase and the enzyme encoded by the MMP9 gene degrades Type IV and V collagens. Lower expression of MMP-9 in DN rats may result in increased expression of Type IV collagen in tubular epithelial cells or mesangial cells. 13 Tissuespecific inhibitor of metalloproteinase-1 is a potent inhibitor of activated MMPs and can inhibit MMP-9 activity. 39 In the present study, TIMP-1 was overexpressed in DN compared with control rats, which may explain the low expression of MMP-9 and the high expression of Type IV collagen in DN rats. Oral deferiprone treatment promoted MMP-9 expression and inhibited TIMP-expression, and further alleviated the renal injury, as evidenced by the results of histopathological analyses. However, recent studies suggest that there is enhanced MMP-9 and reduced Type IV collagen in DN rats and MMP-9 knockout attenuates DN by modulation of podocyte function and dedifferentiation. 40, 41 Therefore, the role of MMP-9 in DN requires further exploration. In addition, the present study is a preliminary study in animals and the mechanisms and signaling pathways underlying the action of deferiprone used for clinical DN remain unclear. There is a long way to go before deferiprone can be considered for clinical use in DN patients.
In summary, the results of the present study indicate that iron chelation following oral administration of deferiprone has a renoprotective effect by relieving oxidative stress, inflammation, and fibrosis of the tubulointerstitium in DN rats.
